focus -WSS

focus

author：leisure time 2025-10-01 07:42:15 - browse：28167

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： New details revealed about Purdue's marketing of OxyContin

WSS

'Reaching a detente': STAT's Helen Branswell on covering Covid

Celebrate National Dole Whip Day for 3 days this week at Disney

India sets sights on home

ActiGraph execs on goal of drug approvals with digital endpoints

As Maui death toll rises, number of missing remains unclear

As Maui death toll rises, number of missing remains unclear

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Listen: Racing for gene therapy & a pioneering approval

New air purifier tech could be key to improving indoor air quality

Eye stem cell transplant could help restore vision in injured people

Anesthesiologist group: stop taking Ozempic before surgery

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Trump demands the U.S. pay no more for drugs than other countries … again

Ebola public health emergency is over, WHO declares

Affirmative action in medical school literally saved lives

Living with Hashimoto's and celiac disease, and med school, too

knowledge

Stanford president to resign after investigation of research

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

'Reaching a detente': STAT's Helen Branswell on covering Covid

Stanford president to resign after investigation of research

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

explore

Wikipedia

hotspot

focus